Trevi Therapeutics
TRVI
37 hedge funds and large institutions have $83.3M invested in Trevi Therapeutics in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 13 closing their positions.
18% more capital invested
Capital invested by funds: $70.5M → $83.3M (+$12.9M)
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
6.41% less ownership
Funds ownership: 78.48% → 72.07% (-6.4%)
8% less funds holding
Funds holding: 40 → 37 (-3)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
91% less call options, than puts
Call options by funds: $2K | Put options by funds: $22K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$2.48M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$956K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$300K |
| 4 |
Millennium Management
New York
|
+$232K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$227K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.4M |
| 2 |
ACM
Altium Capital Management
New York
|
-$1.64M |
| 3 |
AC
Armistice Capital
New York
|
-$1.33M |
| 4 |
Morgan Stanley
New York
|
-$844K |
| 5 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$588K |
TRVI Hedge Fund Activity: Q4 2022 in Review
37 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q4 2022, worth a combined $83.3M — up 18% from $70.5M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of TRVI and 10 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 9 added.
The largest buyer was Frazier Life Sciences Management, adding an estimated $2.48M. The largest seller was Fidelity Investments, exiting entirely with an estimated $2.4M sold.
- 37 institutional investors held Trevi Therapeutics (TRVI) as of Q4 2022, down from 40 in Q3 2022.
- Funds reported $83.3M of Trevi Therapeutics stock for Q4 2022, up 18% quarter-over-quarter.
- 10 funds opened new Trevi Therapeutics positions in Q4 2022 and 13 closed out, a net change of -3 holders.
- The largest Trevi Therapeutics buyer in Q4 2022 was Frazier Life Sciences Management, an estimated $2.48M added.
- The largest Trevi Therapeutics seller in Q4 2022 was Fidelity Investments, an estimated $2.4M sold.
Based on aggregated 13F filings for Q4 2022.